Chickenpox Clinical Trial
Official title:
The Epidemiology and Economic Impact of Varicella Related Hospitalization in Turkey (VARICOMP Study)
Epidemiological information on varicella complications in children is essential for the development of appropriate immunization recommendations. Economic analyses of varicella immunization are sensitive to the costs of hospitalized cases, so there is a need to validate varicella-related hospitalization data in a country-specific manner. These data also provide a baseline for comparison with data collected after routine varicella immunization to evaluate the overall impact and cost-effectiveness of varicella immunization programs. Knowledge about the cause and incidence of varicella-related hospitalizations in Turkey is limited, center-specific and not sufficiently accurate. The aim of this multicenter study (VARICOMP) was to estimate the annual incidence of pediatric varicella-related hospitalization, describe the associated complications and estimate the annual mortality and economic cost of these cases.
Varicella infection is one of the common childhood infectious disease. While usually
self-limiting, a case of varicella can develop complications -sometimes potentially serious-
requiring hospitalizations including secondary bacterial infections (mainly at the skin and
skin structure), respiratory complications (pneumonia or exacerbation of asthma),
neurological complications (encephalitis and cerebellitis). Most hospitalizations for
varicella occurred in children who were previously healthy and can cause significant long
term sequele and mortality in immunocompetent as well as immunocompromised children.
Incidence of varicella and related hospitalization rates changes according to climates and
also the presence of vaccination. WHO recommended that routine childhood varicella
vaccination be considered in countries where the disease is a relatively important public
health and socioeconomic problem however live attenuated varicella introduced to the
childhood immunization programmes in Australia, Canada, Germany, Greece, Qatar, Republic of
Korea, Saudi Arabia, Taiwan, United States, Uruguay, and parts of Italy and Spain. Clinically
and statistically significant reduction in varicella-related hospitalizations for children
and adults associated with childhood varicella immunization and a corresponding significant
decrease in hospital charges.
Epidemiological information on varicella complications in children is essential to develop
immunization recommendation strategies. Economic analyses of varicella immunization are
sensitive to the costs of hospitalized cases, so there is a need to validate varicella
related hospitalization data at the country-based level. The data also provide a baseline for
the data after routine varicella immunization to evaluate the overall impact and
cost-effectiveness of varicella immunization programs. Knowledge about the cause and
incidence of varicella related hospitalization are limited and center-specific in Turkey and
cannot provide sufficiently accurate information. Varicella infections have been commonly
seen in children in Turkey and VZV seroprevalence increased with age and 70% at the age of 7
years and 90% in 15-19 years. Varicella vaccine is available in private practice in Turkey
and estimated coverage is lower than 10%.
The aim of this multicenter study (VARICOMP study) to estimate the annual incidence of
pediatric varicella related hospitalizations, describe the complications and estimate annual
mortality and cost in children.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02570126 -
A Safety and Immune Study of 2 Types of GlaxoSmithKline's Varicella Vaccines Given as a 2-doses Course to Healthy Children 12-23 Months of Age.
|
Phase 3 | |
Completed |
NCT00326183 -
Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)
|
Phase 4 | |
Completed |
NCT02452229 -
Review of Human Herpes Viruses in Burns
|
N/A | |
Completed |
NCT01815073 -
Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine
|
Phase 4 | |
Completed |
NCT01817270 -
Immunogenicity and Safety Study of 2 Doses of Live Attenuated Varicella Vaccine
|
Phase 4 | |
Active, not recruiting |
NCT01982409 -
Immune Persistence After Inoculated With One-dose Freeze-Dried Live Attenuated Varicella Vaccine in Children Vaccine in Children
|
Phase 4 | |
Completed |
NCT00921999 -
Immune Response to Varicella-Zoster Vaccination and Infection
|
N/A | |
Completed |
NCT00098046 -
Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection
|
Phase 3 | |
Completed |
NCT05732337 -
Open Clinical Investigation to Evaluate the Effectiveness and Safety of a Topical Medical Device.
|
N/A | |
Completed |
NCT01684072 -
Safety and Immunogenicity Study of Live Attenuated Vaccine Against Varicella Without Gelatin
|
Phase 4 | |
Completed |
NCT00156559 -
MMR and Varicella Vaccine in Premature Infants
|
Phase 4 | |
Active, not recruiting |
NCT05084508 -
A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age
|
Phase 2 | |
Completed |
NCT04384016 -
Safety and Immunogenicity of Skyvaricella Injection in Healthy Volunteer Vietnamese Children From 12 Months to 12 Years Old
|
Phase 4 | |
Completed |
NCT00001125 -
Use of a Varicella-Zoster Virus (VZV) Vaccine to Prevent Shingles in HIV-Infected Children Who Have Already Had Chickenpox
|
Phase 1 | |
Completed |
NCT00002358 -
A Study of BV-araU in the Treatment of Varicella-Zoster Viral Disease (VZV) in HIV-Infected Children Who Have Not Had Success With or Who Cannot Take Other Treatments for VZV
|
Phase 3 | |
Completed |
NCT00000953 -
Comparison of Brovavir Versus Acyclovir in the Treatment of Herpes in HIV-Infected Patients
|
Phase 2 | |
Withdrawn |
NCT00001054 -
The Safety and Effectiveness of Valacyclovir HCl in the Treatment of Herpes Simplex or Varicella/Zoster Infections in HIV-1 Infected Children
|
Phase 1 | |
Completed |
NCT00002315 -
A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients With Weakened Immune Systems
|
Phase 3 |